PROGESTOGEN THERAPY FOR DES-INDUCED CV ABNORMALITIES

孕激素治疗 DES 引起的 CV 异常

• 批准号: 3187265
• 负责人: Lovell Allan Jones
• 金额: $ 7.71万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-09-01 至 1990-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3187265
• 关键词: Rodentias; cervix disorder; computer simulation; cytoplasm; diethylstilbestrol; dosage; estradiol; ethinyl estradiol; human therapy evaluation; laboratory mouse; mathematical model; medroxyprogesterone; newborn animals; progesterone; reproductive system disorder chemotherapy; vagina disorder

Clinical evidence suggests that progesterone may reduce the presence of adenosis in the genital tracts of diethylstilbestrol (DES)-exposed human females. Testing of the efficacy of progesterone therapy for the DES exposed human female is proposed in this study using the neonatally estrogen treated mouse as the model system. Neonatal female BALB/c mice will receive subcutaneous injections of 1 or 25 ug of estradiol (E2) for five days beginning 24 hours following birth. The mice will be weaned at 25 days and randomly distributed among the following experimental groups: A) animals receiving no further treatment, B) those receiving a high dose of Provera (R, C) those receiving a high dose of Provera (R) and ethinyl-estradiol-17, and D) those receiving ethinyl-estradiol 17B only. All groups will receive normonal treatment via silastic implants. Treatment will begin at two months of age and will continue for one year. Mice from each group will be selected at three month intervals and subjected to vaginal smears for ten consecutive days followed by sacrifice. One half of the cervicovaginal (CV) tract will be frozen and then analyzed for the presence of cytoplasmic and nuclear P receptor (PR) and E (ER) receptor. The other half of the CV tract will also be frozen and sectioned for histologic examination.

临床证据表明，黄体酮可能会降低 己烯雌酚生殖道中存在腺病 (DES) 暴露的人类女性。 功效测试 对暴露于 DES 的女性进行黄体酮治疗 在这项研究中提出使用新生雌激素治疗的小鼠 作为模型系统。 新生雌性 BALB/c 小鼠将接受 皮下注射 1 或 25 ug 雌二醇 (E2)，持续 5 次 出生后 24 小时开始的天数。 小鼠将断奶 25 天后随机分布在以下组中 实验组：A) 不接受进一步治疗的动物， B) 接受高剂量 Provera 的患者 (R, C) 接受高剂量 Provera 的患者 高剂量 Provera (R) 和乙炔雌二醇-17，以及 D) 那些 仅接受乙炔雌二醇 17B。 所有团体都会收到 通过硅橡胶植入物进行常规治疗。 治疗将于 两个月大，并将持续一年。 老鼠来自 每组将每隔三个月进行一次选择并接受 连续十天进行阴道涂片检查，然后处死。 一半的宫颈阴道 (CV) 道将被冷冻，然后 分析细胞质和核 P 受体的存在 (PR) 和 E (ER) 受体。 CV 的另一半也将 冷冻并切片用于组织学检查。